About Oragenics (NYSEAMERICAN:OGEN)
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on Assets-94.88%
Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions
What is Oragenics' stock symbol?
Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."
When did Oragenics' stock split? How did Oragenics' stock split work?
Shares of Oragenics reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.
How were Oragenics' earnings last quarter?
Oragenics, Inc. (NYSEAMERICAN:OGEN) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.20) earnings per share for the quarter. View Oragenics' Earnings History.
Who are some of Oragenics' key competitors?
Some companies that are related to Oragenics include Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Monash IVF Gr (MVF), Horizon Discovery (HZD), ImmunoVaccine (IMV), Adherex Technologies (FRX), ImmunoVaccine (IMMVF), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC) and Tiziana Life Sciences (TILS).
Who are Oragenics' key executives?
Oragenics' management team includes the folowing people:
- Dr. Alan F. Joslyn Ph.D., Pres, CEO & Director (Age 59)
- Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 62)
- Dr. Martin Handfield M.Sc., Ph.D., Sr. VP of Discovery Research (Age 47)
- Dr. Guojun Nie Ph.D., Director of Process Devel.
- Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant
Has Oragenics been receiving favorable news coverage?
Media coverage about OGEN stock has been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Oragenics earned a media sentiment score of 0.09 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 44.63 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Oragenics?
Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oragenics' stock price today?
One share of OGEN stock can currently be purchased for approximately $1.47.
How big of a company is Oragenics?
Oragenics has a market capitalization of $105.48 million.
How can I contact Oragenics?
Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900.
MarketBeat Community Rating for Oragenics (OGEN)MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Oragenics (NYSEAMERICAN:OGEN) Analyst Ratings History
(Data available from 4/26/2016 forward)
Oragenics (NYSEAMERICAN:OGEN) Earnings History and Estimates Chart
Oragenics (NYSEAMERICAN OGEN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/16/2016||Q1 2016||($0.50)||$0.26 million||View||N/A|
|3/30/2016||Q4 2015||($0.60)||$0.24 million||View||N/A|
|11/6/2015||Q3 2015||($0.50)||$0.33 million||View||N/A|
|8/7/2015||Q2 2015||($1.70)||$0.24 million||View||N/A|
|5/8/2015||Q1 2015||($0.40)||$0.36 million||View||N/A|
|2/27/2015||Q4 2014||($0.30)||$0.22 million||View||N/A|
|11/3/2014||Q3 2014||($0.30)||$0.20 million||View||N/A|
|8/7/2014||Q2 2014||($1.00)||($0.50)||$0.30 million||View||N/A|
|2/28/2014||Q4 2013||($0.90)||($0.90)||$0.44 million||View||N/A|
|10/25/2013||Q3 2013||($3.40)||$0.25 million||View||N/A|
|8/12/2013||Q2 2013||($0.50)||($0.80)||$0.17 million||View||N/A|
|5/15/2013||Q1 2013||($0.90)||($0.60)||$0.18 million||View||N/A|
Oragenics (NYSEAMERICAN:OGEN) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Oragenics (NYSEAMERICAN OGEN) Insider Trading and Institutional Ownership History
Oragenics (NYSEAMERICAN OGEN) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/30/2016||Randal J Kirk||Major Shareholder||Buy||2,261,419||$0.52||$1,175,937.88|| |
|12/12/2014||Family Lp Koski||Major Shareholder||Buy||18,686||$0.81||$15,135.66|| |
|12/11/2014||Family Lp Koski||Major Shareholder||Buy||13,000||$0.85||$11,050.00|| |
|12/10/2014||Family Lp Koski||Major Shareholder||Buy||5,800||$0.89||$5,162.00|| |
|12/3/2014||Family Lp Koski||Major Shareholder||Buy||8,800||$0.89||$7,832.00|| |
|12/1/2014||Family Lp Koski||Major Shareholder||Buy||15,000||$0.93||$13,950.00|| |
|11/25/2014||Family Lp Koski||Major Shareholder||Buy||2,200||$0.92||$2,024.00|| |
|11/24/2014||Family Lp Koski||Major Shareholder||Buy||2,800||$0.95||$2,660.00|| |
|11/19/2014||Family Lp Koski||Major Shareholder||Buy||24,546||$0.85||$20,864.10|| |
|11/14/2014||Fred Telling||Director||Buy||27,000||$0.95||$25,650.00|| |
|11/13/2014||Family Lp Koski||Major Shareholder||Buy||13,000||$0.84||$10,920.00|| |
|11/12/2014||Family Lp Koski||Major Shareholder||Buy||15,100||$0.85||$12,835.00|| |
|11/11/2014||Family Lp Koski||Major Shareholder||Buy||7,000||$0.85||$5,950.00|| |
|8/13/2014||John N Bonfiglio||CEO||Buy||1,000||$1.70||$1,700.00|| |
|3/26/2014||Alan W Dunton||Director||Sell||12,000||$3.02||$36,240.00|| |
|3/26/2014||Family Lp Koski||Major Shareholder||Sell||6,730||$3.07||$20,661.10|| |
|3/20/2014||Alan W Dunton||Director||Sell||2,000||$3.03||$6,060.00|| |
|3/14/2014||Family Lp Koski||Major Shareholder||Sell||8,009||$3.11||$24,907.99|| |
|3/12/2014||Family Lp Koski||Major Shareholder||Sell||9,067||$3.12||$28,289.04|| |
|3/11/2014||Alan W Dunton||Director||Sell||2,375||$3.37||$8,003.75|| |
|12/30/2013||Alan W Dunton||Director||Sell||10,000||$2.85||$28,500.00|| |
|12/23/2013||Alan W Dunton||Director||Sell||5,000||$2.91||$14,550.00|| |
|12/20/2013||Alan W Dunton||Director||Sell||10,000||$2.86||$28,600.00|| |
|12/18/2013||Alan W Dunton||Director||Sell||9,000||$2.83||$25,470.00|| |
|12/13/2013||Alan W Dunton||Director||Sell||7,000||$3.00||$21,000.00|| |
|12/11/2013||Alan W Dunton||Director||Sell||6,000||$3.04||$18,240.00|| |
|12/3/2013||Charles L Pope||Director||Sell||10,000||$3.11||$31,100.00|| |
|11/20/2013||Randal J Kirk||Major Shareholder||Buy||1,242,490||$2.50||$3,106,225.00|| |
|9/30/2013||Randal J Kirk||Major Shareholder||Buy||2,648,510||$3.00||$7,945,530.00|| |
Oragenics (NYSEAMERICAN OGEN) News Headlines
Oragenics (NYSEAMERICAN:OGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Oragenics (NYSEAMERICAN:OGEN) Income Statement, Balance Sheet and Cash Flow Statement
Oragenics (NYSEAMERICAN OGEN) Stock Chart for Thursday, April, 26, 2018